U.S Influenza Vaccines Industry on the Rise: Exploring the Path to USD 8.3 Billion

DELHI, India - Feb. 20, 2024 - PRLog -- Rapid market expansion is primarily due to increased research and development, the introduction of quadrivalent influenza vaccines, the aging population, and vaccine awareness. In addition, expanded recommendations from government and advisory bodies to get influenza vaccines are driving market growth in the United States.

Influenza is the second leading cause of death from vaccine-preventable disease in the United States after COVID-19. Rates of seasonal influenza infection are highest in children, but the risks for complications, hospitalizations, and deaths are higher in adults 65 years of age and older, children younger than 5 years, pregnant women, and people of any age with conditions that place them at increased risk for influenza complications.

The report on the influenza vaccines market in the United States is a comprehensive study and presentation of drivers, restraints, opportunities, demand, market size, forecasts, and trends in the influenza vaccines market in the United States during 2018-2031. In addition, the report is a collective presentation of primary and secondary research findings.

Key Market Developments

The United States continues to be the world's largest influenza vaccines market
Demand for influenza vaccines is expected to increase over the forecast period due to the pandemic COVID -19
Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate
Novavax announces initiation of Phase 2 study for COVID-19 influenza combination vaccine and stand-alone influenza vaccine candidate
GSK and CureVac advance mRNA COVID-19 and influenza vaccine candidates
Seqirus receives a government contract to develop 2 influenza vaccines

Get Free Market Research Reports @ https://dpiresearch.com/report/us-influenza-vaccines-market/